[GLP-1 analogues in treatment of type 1 diabetes mellitus].
The insulin replacement is essential in the treatment of type 1 diabetes. Insulin therapy has been coupled with relevant side effects such as hypoglycemia and weight gain. Glucagon-like Peptide 1(GLP-1) analogues (liraglutide) and incretin mimetics (exenatide) are approved only for the treatment of type 2 diabetes mellitus. This review aims to answer the question of what effects exercise GLP-1 analogues on glucose metabolism in people with type 1 diabetes mellitus. A systematic literature search. We included studies in people with diabetes mellitus type 1 and GLP-1 analogues intervention. The report quality, the methodological quality of the studies and reviews was based on CONSORT and PRISMA assessed. A total of 19 potentially relevant publications 219 hits were identified. Included were four randomized-controlled trials, two non-randomized-controlled trials and five reviews. The studies and reviews have shown a different methodological quality. There were significant changes in insulin dose (p ≤ 0.01) reduced Hyperglykämierate detected (p ≤ 0.01) reduction of blood glucose variations (p ≤ 0.01) and a reduction in glucagon (p ≤ 0.05). The delayed gastric emptying and reduction of glucagon is the main mechanism of the improved glycemic control in the glucose metabolism of type 1 diabetes. The present literature shows promising results for the additional substitution of GLP-1 analogues in the treatment of type 1 diabetes mellitus. Based on the current data, there is a need to carry out large randomized-controlled trials.